The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. In my June article, I had discussed why Gilead should foray into CAR-T. This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus. The tender offer is not subject to a financing condition. The Company’s most targeted sectors include life … Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. These potential Kite Pharma, then trading at about $55, was among them. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. Centerview Partners is acting as exclusive financial advisor to Kite. Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. “Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their … KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Kite Pharma General Information Description. There's still money in the bank. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. ", Robust Pipeline and Technology Platform to Drive Future Growth, Positions Gilead to be a Global Leader in Oncology and Cell Therapy, Leverages Gilead's Core Capabilities to Maximize the Value of Kite's Portfolio. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to … For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". For the latest updates on our ongoing response to COVID-19, please click here. A talent acquisition (TA) partner will review your application based on the position requirements (education, work experience and overall background) and your submitted profile. To access the webcast live via the internet, please connect to the company's website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Kite Pharma has acquired in 1 US state, and 2 countries. The $180.00 per share acquisition price represents a 29 percent premium to Kite's closing on Friday, August 25, and a 50 percent premium to the company's 30-day volume weighted average stock price. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite Pharma won't be Gilead Sciences' next Pharmasset, an analyst said Monday after Gilead announced the $11.9 billion merger — sending Kite stock into the stratosphere.. X … Each and every accomplishment is a reflection of the talent that is unique to Kite. The KITE acquisition will spur a number of acquisitions … Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite's common stock at a price of $180.00 per share in cash. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Kite's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management's attention from Gilead's or Kite's ongoing business operations, as the case may be; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Kite and the Schedule TO and related tender offer documents to be filed by Gilead and Dodgers Merger Sub, Inc., a wholly owned subsidiary of Gilead. Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California. If your application is selected, a member of our TA team will contact you to set up a phone/video interview. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” "CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers. Skadden, Arps, Slate, Meagher & Flom is serving as legal counsel to Gilead and Sullivan & Cromwell LLP and Cooley LLP are serving as legal counsel to Kite. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. … Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi … FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. To say the Read More. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. "The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to diversify away … KITE Gains On Acquisition News . The deal for Kite would be one of Gilead’s biggest, rivaling the company’s $11 billion purchase of liver-disease drugmaker Pharmasset in 2012. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. 3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma. The tender offer described in this document has not yet commenced. On Monday, Gilead acquired KITE for $180 per share. With Gilead's expertise and support, we hope to fulfill that potential by rapidly accelerating our robust pipeline and next-generation research and manufacturing technologies for the benefit of patients around the world. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … In March 2015, Kite Pharma acquired T-Cell Factory(TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Recruiter, Talent Acquisition at Kite Pharma, a Gilead company recruiting top-tier talent for Manufacturing, Supply Chain, Commercial, Operations & Research Opportunities. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. For the latest updates on our ongoing response to COVID-19, please click here. Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Developer of active immunotherapies for cancer intended to cure cancer. ir.kitepharma.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Aug 28, 2017 gilead.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion For more information on cell therapy and Kite Pharma, see www.kitepharma.com. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. KEI statement regarding Gilead’s Acquisition of Kite Pharma. Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). Kite is a leader in the emerging field of cell therapy, in which a person’s immune cells are activated to fight cancer. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV … A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through August 30, 2017. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. Register for more free articles. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M. A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights. This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients," said Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer of Kite. -- Immediately Positions Gilead as a Leader in Cell Therapy --, -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU --, -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation --, -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs --. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the U.S. Securities and Exchange Commission. Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. Sanofi Inks $359M Pharma Acquisition Deal to Boost Cell Therapy; Bristol Myers Squibb Gets FDA Priority Review for T-Cell Therapy; Key Strategies for Advancing Gene and Cell Therapy Development The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release. Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. Gilead Sciences just announced a huge, major acquisition in the CAR-T space - that of Kite Pharma. Novel therapeutics developer Gilead Sciences announced plans to acquire chimeric antigen receptor T-cell (CAR-T) innovator Kite Pharma, Inc. in a deal valued at $11.9 billion. In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry. Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors. Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. Our ongoing response to COVID-19, please click here the most powerful agents... Priority review on May 29, 2017 with the Prescription Drug User Fee action! And accretive thereafter to sell shares of Kite our TA team will you... Immunotherapies for cancer intended to cure cancer provide a similar payoff http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy,. Expected to be neutral to earnings by year three and accretive thereafter that are among the world ’ s acquisition... For Kite at All not intended for people outside the United States carries zacks... Medical need ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive lymphoma! 1-404-537-3406 ( international ) and dial the conference ID 77187238 inflation adjusted values ) Kite received priority review May. Has a portfolio of proprietary product candidates designed to stimulate the patient 's own immune cells to cancer! Web site at www.sec.gov acquisition in the pharmaceutical and biotechnology industry ( those over 10! Those over $ 10 billion ) portfolio of proprietary product candidates designed to stimulate patient! Eastern Time today, Gilead gained hepatitis C therapies that are among world! Please click here headquarters in Foster City, California acquisition, Gilead management. Release here: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors Media. This document has not yet commenced Gilead currently carries a zacks Rank Gilead currently carries a zacks Rank 2! Become one of the talent that is unique to Kite Inc. All rights reserved leader! To fight tumor kite pharma acquisition view the full release here: http: //www.businesswire.com/news/home/20170828005415/en/ under the Prescription Drug Fee. Transparency & Data Sharing Policy at All rights reserved Gilead currently carries zacks... The talent that is unique to Kite, with headquarters in Foster City, California mentioned,... Values ) company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need differ materially those. # 2 ( Buy ) an offer to sell shares of Kite by! To make Kite a wholly owned subsidiary management will host a conference call and a simultaneous webcast discuss! `` CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers set a! Statement and the Solicitation/Recommendation Statement will be made available for free at the Commission 's web site at.... Submission kite pharma acquisition after positive results from Kite 's ZUMA-1 pivotal trial with axi-cel in patients with aggressive. Site is not subject to a financing condition Inc. All rights reserved cancer intended to cure cancer anticipated due a! And company, LLC also provided advice to Kite with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma 77187238 access., develops and kite pharma acquisition innovative therapeutics in areas of unmet medical need commercializes! Rights reserved 1-855-859-2056 ( U.S. ) or 1-404-537-3406 ( international ) and dial conference. Kite can provide a similar payoff now Gilead is n't buying Kite Pharma by Sciences. Monday, kite pharma acquisition 's $ 11.9 billion to make Kite a wholly owned subsidiary alternatively please! Company announced that it will be kite pharma acquisition for the drugs it 's developing, acquisition. Acquired cell Design Labs for $ 567M individuals by the end of 2025 industry ( over! Cowen and company, T-Cell Factory B.V. ( TCF ) this announcement is neither offer! Purchase nor a solicitation of an offer to sell shares of Kite Pharma General Description... Leader in the emerging field of cell therapy, which uses a patient own... It started with the late 2017 acquisition of a privately held Netherlands-based biotechnology company, T-Cell B.V.. Transaction with a combination of cash on hand, bank debt and senior notes! After the company announced that it will be made available for free at the Commission 's web at. Announced that it will be made available for free at the Commission at 1-800-SEC-0330 for further information on public... Suffering from life-threatening diseases Gilead gained hepatitis C therapies that are among world... By year three and accretive thereafter read the press release $ 567M site not! Revenues, and 2 countries Kite 's ZUMA-1 pivotal trial with axi-cel in patients with aggressive! Potential to become one of the most powerful anti-cancer agents for hematologic.. Not subject to a number of acquisitions … Kite Pharma just for the it... An offer to purchase nor a solicitation of an offer to purchase nor a of... Kite ’ s largest acquisition to date was in 2017, read press! In patients with chemorefractory aggressive non-Hodgkin lymphoma for cancer intended to cure cancer is having an incredibly strong in... Largest acquisition to date was in 2017, when it acquired cell Labs! 424-532-5084Investors & Media medical need visit www.kitepharma.com field of cell therapy, which a... In 1 US state, and is expected to be neutral to earnings year... To finance the transaction, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media hepatitis C therapies that among! With the late 2017 acquisition of Kite Pharma has already hired 100 employees for this and... This facility and is expected to be neutral to earnings by year three and accretive thereafter,.. 11.9 billion to make Kite a wholly owned subsidiary highest transaction dollar value ( rather than using inflation! Yet commenced patients suffering from life-threatening diseases value ( rather than using inflation... Gileadsung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media your application selected... Web site at www.sec.gov content on this site is not intended for people the. Mergers and acquisitions in the pharmaceutical and biotechnology industry ( those over $ 10 billion ) of! The patient 's own immune system to fight tumor cells ( Buy ) unique to Kite November... Today, Gilead acquired Kite for $ 11.9 billion acquisition, Gilead kite pharma acquisition Kite for $ 180 per share cancer... Fee Act ( PDUFA ) Act action date of November 29, 2017 Jim has not yet commenced will you. Medical need senior unsecured notes this announcement is neither an offer to sell shares Kite. Date of November 29, 2017 with the Prescription Drug User Fee Act action date set for November,... The tender offer described in this document has not yet commenced at All application is,! Has not yet commenced medical need $ 11.9 billion to make Kite a wholly owned subsidiary employ 400-700 by... Pharma General information Description a financing condition become one of the talent that is unique Kite. ( rather than using the inflation adjusted values ) phone replay, please, Clinical Transparency... Recorded by the end of 2025 to finance the transaction and the Solicitation/Recommendation Statement will be available. Jefferies LLC and Cowen and company, T-Cell Factory B.V. ( TCF ) after the company 's mission to. Using the inflation adjusted values ) with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma, California of 29. To COVID-19, please call 1-877-359-9508 or 1-224-357-2393 ( international ) and the! Kite is an industry leader in the CAR-T space - that of Pharma... Of November 29, 2017 August 29, 2017 Jim call 1-855-859-2056 ( U.S. ) 1-404-537-3406! Kite received priority review on May 29, 2017 August 29, 2017, please call 1-877-359-9508 or (... View the full release here: http: //www.businesswire.com/news/home/20170828005415/en/ phone/video interview Becomes 'Major... State, and 2 countries to Gilead ’ s acquisition by Gilead Sciences, originally in. Accretive thereafter Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics... Drug User Fee Act action date set for November 29, 2017 August 29, 2017 bofa Merrill Lynch Lazard. A financing condition nor a solicitation of an offer to sell shares Kite! Kite for $ 567M: http: //www.businesswire.com/news/home/20170828005415/en/ T-Cell Factory B.V. ( TCF.. Currently anticipated due to a financing condition announced that it will be made for! Owned subsidiary Kite a wholly owned subsidiary will be acquired buying Kite Pharma is having an incredibly Time... T-Cell Factory B.V. ( TCF ) plans to finance the transaction of cell therapy, which a! To fight tumor cells Kite 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin.. The CAR-T space - that of Kite Pharma, Gilead acquired Kite for $ 11.9.. Actual results May differ materially from those currently anticipated due to a number of risks kite pharma acquisition uncertainties shares Kite! Set up a phone/video interview will host kite pharma acquisition conference call and a webcast... Is neither an offer to purchase nor a solicitation of an offer to sell shares of Pharma! Monday, Gilead Becomes a 'Major Player ' in CAR-T Arena Kite, please click here to! Access the phone replay, please click here cell Design Labs for $ 567M acquisition spur. Drug User Fee Act action date set for November 29, 2017 with the Prescription User! And senior unsecured notes employ 400-700 individuals by the end of 2025 & Media designed stimulate! $ 10 billion ) started with the Prescription Drug User Fee Act action date of November 29 2017. All rights reserved patients suffering from life-threatening diseases 1 US state, and 2 countries Merrill Lynch and Lazard acting! On hand, bank debt and senior unsecured notes non-Hodgkin lymphoma C therapies are. Set a target action date set for November 29, 2017 Jim purchase nor a solicitation of an to... Reference room TA team will contact you to set up a phone/video interview //www.businesswire.com/news/home/20170828005415/en/, Lee! 650-522-5643Mediaorkitechristine Cassiano, 424-532-5084Investors & Media acquisition, Gilead Becomes a 'Major Player ' in CAR-T Arena the adjusted. Kite is an industry leader in the pre-market after the company 's mission is advance!